Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient’s suffering from Behçet’s Disease.
Key Highlights
· 12-month option agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Pentoxifylline (tPTX), a treatment for oral ulcers in patient’s suffering from Behçet’s Disease which currently has no cure
· Phase 2 trial successfully completed, demonstrating superiority over standard of care
· Secured Orphan Drug Designation and Fast Track Designation from the FDA
· Positioned for a potential 505(b)(2) approval pathway in the U.S.